Hims & Hers Launches Compounded Version of Wegovy Amid Legal Threats from Novo Nordisk
Telehealth company Hims & Hers announced plans to introduce a less expensive, off-brand variant of the weight-loss medication Wegovy. This move comes shortly after Novo Nordisk, the medication’s manufacturer, released a reformulated version of the highly sought-after drug.
This development underscores the intensifying competition and regulatory scrutiny surrounding GLP-1 medications, which have dramatically changed the landscape of weight-loss treatments in the United States.
Key Developments
- Hims will offer its compounded Wegovy pill at an introductory price of $49 for the first month, increasing to $99 thereafter, significantly lower than Novo Nordisk’s price of $149 per month.
- In response, Novo Nordisk intends to pursue legal action against Hims, labeling the new product as an untested and unauthorized imitation of semaglutide.
- The FDA has previously cautioned Hims regarding misleading marketing claims concerning its compounded medications.
- While the FDA has suggested that compounded versions of GLP-1 drugs would no longer be permitted starting in 2024, exceptions remain for custom prescriptions.
Full Report
New Product Announcement
Hims & Hers declared its intent to launch a compounded pill version of Wegovy, which has gained immense popularity for its efficacy in weight management. This announcement follows Novo Nordisk’s latest reformulation of the drug and marks Hims’ ongoing efforts to tap into the lucrative GLP-1 market.
Legal Challenges
Novo Nordisk swiftly responded to the Hims announcement, asserting it would take legal actions to protect its intellectual property. The Danish pharmaceutical giant described Hims’ product as an “unapproved, inauthentic, and untested knockoff,” raising concerns about patient safety and the integrity of the United States’ drug approval processes.
Regulatory Landscape
Despite warnings from the FDA, Hims has maintained its market presence by offering compounded medications, which fall outside the stringent federal regulations that govern standard pharmaceuticals. The recent warning from the FDA highlighted issues with Hims’ marketing tactics, suggesting that they implied equivalency with FDA-approved GLP-1 treatments.
Market Impact
After the news broke, shares of Novo Nordisk experienced a decline of over 8%. Hims’ new pricing strategy, which positions its product as a more affordable alternative, may attract many patients willing to pay out-of-pocket for weight-loss solutions.
Claims of Personalization
Dr. Craig Primack, head of weight-loss products at Hims, emphasized the company’s position by highlighting the ability to offer customized dosages of GLP-1 drugs based on individual patient needs. He stated that the new pill could provide a preferred mode of administration compared to injections, further tailoring treatment to patients’ preferences.
Context & Previous Events
In recent months, the FDA has indicated that GLP-1 drugs would no longer be considered in short supply, potentially phasing out the authorization for compounded versions. However, the agency allows the compounding of medications when specifically tailored for patient prescriptions. In September, the FDA had already issued a warning to Hims regarding misleading marketing claims related to its compounded GLP-1 products, signaling a growing scrutiny in this burgeoning market.
